40044-37-9

Upstream product

• 590-67-0 1-Methylcyclohexanol 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 1439366-58-1 (1-methylcyclohexyl) N-[(2S,3R)-2-methyl-4-oxo-oxetan-3-yl]-carbamate 
• 40044-39-1 (1-methylcyclohexyl) N-aminocarbamate 
• 1439367-24-4 (2S,3R)-3-hydroxy-2-[(1-methylcyclohexyloxy)carbonylamino]butanoic acid 

Relevant academic research and scientific papers

Disubstituted beta-lactones as inhibitors of N-acylethanolamine acid amidase (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.

DISUBSTITUTED BETA-LACTONES AS INHIBITORS OF N-ACYLETHANOLAMINE ACID AMIDASE (NAAA)

The present invention provides compounds and pharmaceutical compositions for inhibiting N-acylethanolamine acid amidase (NAAA). Inhibition of NAAA is contemplated as a method to sustain the levels of palmitoylethanolamide (PEA) and oleylethanolamide (OEA), two substrates of NAAA, in conditions characterized by reduced concentrations of PEA and OEA. The invention also provides methods for treating inflammatory diseases and pain, and other disorders in which decreased levels of PEA and OEA are associated with the disorder.